Aphena Pharma to complete expansion of Solid Dose Division by April
Category: #health  By Pankaj Singh  Date: 2021-01-27
  • sharesocial_share_icon
  • Twitter
  • Facebook
  • LinkedIn

Aphena Pharma to complete expansion of Solid Dose Division by April

Aphena Pharma Solutions, a pharmaceutical services provider, has reportedly announced the continuous expansion of its Tennessee-based Solid Dose Division worth $21 million. This division is expected to be completed by 1st April 2021.

The expansion, announced in September 2020, includes the takeover of a 500,000-sq.ft. property that was purpose-built for the manufacturing & packaging operations of the FDA. It also represents the expansion of Aphena into biologics, 3rd-party logistics distribution, and cold chain storage, with 47,000-sq.ft. of the cold chain storage currently available.

The latest progress has enabled Aphena to further expand its bottle packaging capacity with the initial installation of 10 high-speed bottling lines for solid-based products such as gel caps, soft gels, caplets, capsules, and tablets. The company is further planning to install 30 more high-speed lines in this new facility in the future, boosting its monthly capacity to nearly 80 million bottles as well as becoming a strategic partner in the industry for pharmaceutical solid dose packaging.

The turnkey bottling services of Aphena include purchasing all the primary & secondary packaging materials such as pharmaceutical bottle labeling with the serialization support. Various configurations and sizes like square bottles are also available. In addition, the company has the capability to efficiently run batches of over 1,000 to 10 million bottles under the cGMP quality systems.

According to Eric Allen, EVP of Sales & Marketing at Aphena, the new facility and bottling lines have set the foundation for the future of the company’s solid dose packaging, enabling it to maintain a capacity level of 50% for new projects as well as surge the capacity requirements to increasingly cater to the customers’ needs.

Aphena Pharma is an industry-leading company that provides contract manufacturing & packaging services for the medical device, consumer health, pharmaceutical, and biologics markets. The company, with two FDA- and DEA-registered U.S. locations, handles suspensions, foams, ointments, creams, gels, liquids, solid dose, and lotion-based products.­

Source credit:

https://www.businesswire.com/news/home/20210126005812/en



About Author

Pankaj Singh

Email: [email protected]   linkdin twitter

Pankaj Singh

Pankaj Singh Develops content for Market Size Forecasters, Algosonline, and a couple of other platforms. A Post Graduate in Management by qualification, he worked as an underwriter in the UK insurance domain before deciding to switch his field of profession. With exp...

More News By Pankaj Singh

LVMH revamps La Samaritaine store and opens it in tourist-less Paris

LVMH revamps La Samaritaine store and opens it in tourist-less Paris

By Pankaj Singh

La Samaritaine, a historic landmark of 19th century France, has been reportedly revamped as a new destination for dining, all-in-one shopping, and tourism by LVMH, a French luxury conglomerate. The stores&rs...

Nanjing Bioheng Biotech obtains ODD from US FDA for treating T-ALL

Nanjing Bioheng Biotech obtains ODD from US FDA for treating T-ALL

By Pankaj Singh

Bioheng Biotech Co. Ltd. has reportedly announced that its CD7-targeting T-cell therapy product, code CTD401, has obtained the Orphan Drug Designation (ODD) from the US FDA for treating T-cell acute lymphoblastic leuke...

Tiziana to initiate development of ‘Take Home’ nasal COVID treatment

Tiziana to initiate development of ‘Take Home’ nasal COVID treatment

By Pankaj Singh

Biotechnology company, Tiziana Life Sciences plc, has reportedly announced the submission of a grant to the UK-CTAP (United Kingdom COVID Therapeutics Advisory Panel).

This ...